Humans normally have 46 chromosomes in each cell, divided into 23 pairs. Two copies of chromosome 6, one copy inherited from each parent, form one of the pairs. Chromosome 6 spans about 171 million base pairs (the building blocks of DNA) and represents between 5.5 percent and 6 percent of the total DNA in cells.
Identifying genes on each chromosome is an active area of genetic research. Because researchers use different approaches to predict the number of genes on each chromosome, the estimated number of genes varies. Chromosome 6 likely contains between 1,100 and 1,600 genes.
Genes on chromosome 6 are among the estimated 20,000 to 25,000 total genes in the human genome.
Researchers in the University of Georgia's Regenerative Bioscience Center are visually capturing the first process of chromosome alignment and separation at the beginning of mouse development. The findings could lead to answers to questions concerning the mechanisms leading to birth defects and chromosome instability in cancer cells.
Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.
Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.
The team has completed two genomics studies on the tropical disease, a condition that is estimated to cause up to 30 million illnesses and over a quarter of a million deaths globally each year.
Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), both of which are caused by a mutation in the a gene called C9ORF72.
More than 500,000 people in the United States die each year of cancer-related causes. Now, emerging research has identified the mechanism behind one of the most common mutations that help cancer cells replicate limitlessly.
Using a novel method they developed to map chromosome breaks in a model organism, the budding yeast, Wenyi Feng, Ph.D., of Upstate Medical University and her colleagues have discovered new information as to how and where chromosome fragile sites can occur in human DNA. These sites are frequently observed in cancer cells and are responsible for causing genomic rearrangements.
Scientists from the Spanish National Cancer Research Centre have discovered a new strategy to fight cancer, which is very different from those described to date. Their work shows for the first time that telomeres -- the structures protecting the ends of the chromosomes -- may represent an effective anti-cancer target: by blocking the TRF1 gene, which is essential for the telomeres, they have shown dramatic improvements in mice with lung cancer.
A study led by the Translational Genomics Research Institute has for the first time matched dozens of infantile diseases and syndromes involving muscle weakness and stiff joints to their likely genetic origins.
Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Cancer Cell.
A study revealing fresh insight about chromosome "tails" called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS).
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments...
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Individuals with this altered gene have hereditary hypertension (high blood pressure) and at the same time a skeletal malformation called brachydactyly type E, which is characterized by unusually short fingers and toes. The effect on blood pressure is so serious that -- if left untreated -- it most often leads to death before age fifty.
A new study led by scientists at The Scripps Research Institute sheds light on the cause of some cancers, including breast cancer and leukemia.
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
Huntington's disease is caused by a mutation in the Huntington's disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington's disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease.
Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), an aggressive and lethal form of pediatric cancer.
A new technique that identifies how genes are controlled could help scientists spot errors in the genetic code which trigger disease, a study suggests.
Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.